Clinical Trial

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2024 (before its estimated November 22, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients
Trial Details
NCT Number NCT06276933
Lead Sponsor Tongji University
Collaborators: Shanghai Pulmonary Hospital, Shanghai, China
Conditions Lung Cancer, Camrelizumab
Enrollment 104 participants
Start Date 2024-02-22
Primary Completion 2025-11-22 (estimated)
Study Completion 2026-11-22 (estimated)
Updated on ClinicalTrials.gov 2024-02-26